These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease. Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625 [No Abstract] [Full Text] [Related]
3. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1). Sheng JG; Xu DL; Yu HZ; Xu XR; Tang QM Life Sci; 1987 May; 40(20):2007-10. PubMed ID: 2437428 [TBL] [Abstract][Full Text] [Related]
4. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166 [TBL] [Abstract][Full Text] [Related]
5. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293 [TBL] [Abstract][Full Text] [Related]
6. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Chiueh CC; Markey SP; Burns RS; Johannessen JN; Pert A; Kopin IJ Eur J Pharmacol; 1984 Apr; 100(2):189-94. PubMed ID: 6203759 [TBL] [Abstract][Full Text] [Related]
7. 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Perry TL; Jones K; Hansen S; Wall RA Neurosci Lett; 1987 Mar; 75(1):65-70. PubMed ID: 3106859 [TBL] [Abstract][Full Text] [Related]
8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758 [TBL] [Abstract][Full Text] [Related]
10. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Pifl C; Schingnitz G; Hornykiewicz O Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053 [TBL] [Abstract][Full Text] [Related]
11. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135 [TBL] [Abstract][Full Text] [Related]
12. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
13. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease]. Matsubara K Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975 [TBL] [Abstract][Full Text] [Related]
14. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946 [TBL] [Abstract][Full Text] [Related]
15. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Pifl C; Schingnitz G; Hornykiewicz O Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594 [TBL] [Abstract][Full Text] [Related]
16. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. Schultz W; Scarnati E; Sundström E; Tsutsumi T; Jonsson G Exp Brain Res; 1986; 63(1):216-20. PubMed ID: 3488228 [TBL] [Abstract][Full Text] [Related]
17. Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Booth RG; Trevor A; Singer TP; Castagnoli N J Med Chem; 1989 Feb; 32(2):473-7. PubMed ID: 2783613 [TBL] [Abstract][Full Text] [Related]
18. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
19. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722 [TBL] [Abstract][Full Text] [Related]
20. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Perry TL; Hansen S; Jones K Neurosci Lett; 1987 Feb; 74(2):217-20. PubMed ID: 3494963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]